Ken Griffin Allogene Therapeutics, Inc. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$2.08 - $3.5 $17,264 - $29,050	-8,300 Reduced 60.58%	5,400 $15,000
Q2 2024 Aug 14, 2024	BUY	$2.23 - $4.38 $24,530 - $48,180	11,000 Added 407.41%	13,700 $31,000
Q1 2024 May 15, 2024	SELL	$2.92 - $5.63 $18,688 - $36,032	-6,400 Reduced 70.33%	2,700 $12,000
Q4 2023 Feb 14, 2024	BUY	$2.28 - $3.5 $7,295 - $11,200	3,200 Added 54.24%	9,100 $29,000
Q3 2023 Nov 14, 2023	SELL	$3.17 - $5.96 $27,896 - $52,448	-8,800 Reduced 59.86%	5,900 $18,000
Q2 2023 Aug 14, 2023	SELL	$4.53 - $6.74 $26,274 - $39,092	-5,800 Reduced 28.29%	14,700 $73,000
Q1 2023 May 15, 2023	BUY	$4.92 - $8.21 $29,520 - $49,260	6,000 Added 41.38%	20,500 $101,000
Q4 2022 Feb 14, 2023	SELL	$5.62 - $11.11 $55,076 - $108,878	-9,800 Reduced 40.33%	14,500 $91,000
Q3 2022 Nov 14, 2022	BUY	$10.32 - $17.28 $11,352 - $19,008	1,100 Added 4.74%	24,300 $262,000

163

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $315M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.